News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Kit Includes

Products Included No. Volume Applicaton Dilution Reactivity Homology†
Primary Cocktail 7972 100 µl Immunofluorescence (Immunocytochemistry),
Immunofluorescence (Paraffin)‡
1:100 Human
Monkey
Mouse
Detection Cocktail 7973 100 µl Immunofluorescence (Immunocytochemistry),
Immunofluorescence (Paraffin)‡
1:100 N/A N/A
†Species predicted to react based on 100% sequence homology.
‡Immunofluorescence (Paraffin) protocol recommended unmasking buffer: EDTA
Kit Analytes Detection Dye Ex(max) (nm) Em(max) (nm)
EGF Receptor Alexa Fluor® 555 555 565
Phospho-EGF Receptor (Tyr1068) Alexa Fluor® 488 495 519
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Alexa Fluor® 647 650 665

Product Description

The PathScan® EGF Receptor Activation Multiplex IF Kit offers a novel method to simultaneously monitor the expression, localization, and activation state of EGF receptor, as well as downstream signaling through Erk1/2, using manual immunofluorescence microscopy, or automated imaging and laser scanning high content platforms. This kit contains a cocktail of three high quality primary antibodies targeted against total EGF receptor, phospho-EGF receptor (Tyr1068), and phospho-p44/42 (Erk1/2) (Thr202/Tyr204), as well as a detection cocktail utilizing the Alexa Fluor® series of fluorescent dyes. Antibody and dye pairings have been pre-optimized, and each kit contains enough reagents for 100 assays (based on a working volume of 100 μl/test).


Specificity / Sensitivity

EGF receptor antibody detects endogenous levels of total EGF receptor protein and does not cross-react with other ErbB family members. Phospho-EGF receptor (Tyr1068) antibody detects endogenous EGF receptor only when phosphorylated at Tyr1068. This antibody may cross-react weakly with other tyrosine-phosphorylated proteins. Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody detects endogenous levels of p44 and p42 MAP kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Thr202. This antibody does not cross-react with the corresponding phosphorylated residues of either JNK/SAPK or p38 MAP kinases.


Source / Purification

Monoclonal antibodies were produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase and Tyr1068 of human EGF receptor, or with a fusion protein containing the cytoplasmic domain of human EGF receptor.

The epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane receptor tyrosine kinase that belongs to the HER/ErbB protein family that includes HER2/ErbB2/neu, HER3/ErbB3, and HER4/ErbB4 (1,2). Ligand binding results in receptor homo- and heterodimerization which stimulates its intrinsic tyrosine kinase activity. Autophosphorylation at residues Tyr992, Tyr1045, Tyr1068, Tyr1148, and Tyr1173, as well as c-Src mediated phosphorylation at Tyr845 and Tyr1101 promote docking of SH2 domain-bearing signaling proteins resulting in cellular responses to EGFR activation (2-6). For example, phosphorylation of Tyr1068 facilitates recruitment of Grb2 which, via association with Sos, stimulates the GTP binding activity of Ras, leading to the activation of MAP kinase and other signaling cascades (7). Following activation, EGFR is rapidly endocytosed and either recycled back to the plasma membrane or targeted for lysosomal degradation (8). Dysregulation of EGFR signaling through activating mutations or gene amplification has been implicated in the pathogenesis of many human malignancies, leading to intense clinical study of this pathway (9-13).


1.  Yarden, Y. and Sliwkowski, M.X. (2001) Nature Rev. Mol. Cell. Biol. 2, 127-137.

2.  Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12.

3.  Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9.

4.  Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-4.

5.  Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86.

6.  Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86.

7.  Levkowitz, G. et al. (1999) Mol Cell 4, 1029-40.

8.  Lai, W.H. et al. (1989) J Cell Biol 109, 2741-9.

9.  Rojas, M. et al. (1996) J Biol Chem 271, 27456-61.

10.  Press, M.F. and Lenz, H.J. (2007) Drugs 67, 2045-75.

11.  Baselga, J. (2002) Oncologist 7 Suppl 4, 2-8.

12.  Foon, K.A. et al. (2004) Int J Radiat Oncol Biol Phys 58, 984-90.

13.  Sridhar, S.S. et al. (2003) Lancet Oncol 4, 397-406.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
PathScan® is a trademark of Cell Signaling Technology, Inc.